Bladder-sparing (chemo)radiotherapy in elderly patients with muscle-invasive bladder cancer: a retrospective cohort study

References

• Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104.
   PubMed Web of Science ®Google Scholar
• Booth CM, Siemens DR, Li G, et al. Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study. Clin Oncol (R Coll Radiol). 2014;26(8):506–514.
   PubMed Web of Science ®Google Scholar
• Seisen T, Sun M, Lipsitz SR, et al. Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2017;72(4):483–487.
   PubMed Web of Science ®Google Scholar
• Bekelman JE, Handorf EA, Guzzo T, et al. Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification biasin cancer observational comparative effectiveness research. Value Health. 2013;16(4):610–618.
   PubMed Web of Science ®Google Scholar
• Kaushik D, Wang H, Michalek J, et al. Chemoradiation Vs radical cystectomy for muscle-invasive bladder cancer: a propensity score-weighted comparative analysis using the national cancer database. Urology. 2019;133:164–174.
   PubMed Web of Science ®Google Scholar
• Vashistha V, Wang H, Mazzone A, et al. Radical cystectomy compared to combined modality treatment for Muscle-Invasive bladder cancer: a systematic review and Meta-Analysis. Int J Radiat Oncol Biol Phys. 2017;97(5):1002–1020.
   PubMed Web of Science ®Google Scholar
• Arcangeli G, Arcangeli S, Strigari L. A systematic review and Meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC). Crit Rev Oncol Hematol. 2015;94(1):105–115.
   PubMed Web of Science ®Google Scholar
• Kulkarni GS, Hermanns T, Wei Y, et al. Propensity score analysis of radical cystectomy versus Bladder-Sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic. J Clin Oncol. 2017;35(20):2299–2305.
   PubMed Web of Science ®Google Scholar
• Fonteyne V, Ost P, Bellmunt J, et al. Curative treatment for muscle invasive bladder cancer in elderly patients: a systematic review. Eur Urol. 2018;73(1):40–50.
   PubMed Web of Science ®Google Scholar
• Goossens-Laan CA, Leliveld AM, Verhoeven RH, et al. Effects of age and comorbidity on treatment and survival of patients with muscle-invasive bladder cancer. Int J Cancer. 2014;135(4):905–912.
   PubMed Web of Science ®Google Scholar
• Megwalu II, Vlahiotis A, Radwan M, et al. Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol. 2008;53(3):581–589.
   PubMed Web of Science ®Google Scholar
• Turgeon GA, Souhami L. Trimodality therapy for bladder preservation in the elderly population with invasive bladder cancer. Front Oncol. 2014;4:206.
   PubMedGoogle Scholar
• Witjes J, Lebret T, Comperat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71(3):462–475.
   PubMed Web of Science ®Google Scholar
• Ploussard G, Daneshmand S, Efstathiou JA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014;66(1):120–137.
   PubMed Web of Science ®Google Scholar
• Gomez-Millan J. Radiation therapy in the elderly: more side effects and complications? Crit Rev Oncol Hematol. 2009;71(1):70–78.
   PubMed Web of Science ®Google Scholar
• Smaaland R, Akslen LA, Tonder B, et al. Radical radiation treatment of invasive and locally advanced bladder carcinoma in elderly patients. Br J Urol. 1991;67(1):61–69.
   PubMedGoogle Scholar
• Moonen L, Voet H, de Nijs R, et al. Muscle-invasive bladder cancer treated with external beam radiation: influence of total dose, overall treatment time, and treatment interruption on local control. Int J Radiat Oncol Biol Phys. 1998;42(3):525–530.
   PubMed Web of Science ®Google Scholar
• Simera I, Moher D, Hoey J, et al. A catalogue of reporting guidelines for health research. Eur J Clin Invest. 2010;40(1):35–53.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40(7):939–950.
   PubMed Web of Science ®Google Scholar
• IKNL. Urotheelcelcarcinoom van de blaas, landelijke richtlijn versie 1.0. 2009. Available from: www.oncoline.nl
   Google Scholar
• Boustani J, Bertaut A, Galsky MD, et al. Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: retrospective international study of cancers of the urothelial tract (RISC) investigators. Acta Oncol. 2018;57(4):491–497.
   PubMed Web of Science ®Google Scholar
• Williams SB, Shan Y, Jazzar U, et al. Comparing survival outcomes and costs associated with radical cystectomy and trimodal therapy for older adults with Muscle-Invasive bladder cancer. JAMA Surg. 2018;153(10):881–889.
   PubMed Web of Science ®Google Scholar
• Korpics MC, Block AM, Martin B, et al. Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy. Cancer. 2017;123(18):3524–3531.
   PubMed Web of Science ®Google Scholar
• Bamias A, Tsantoulis P, Zilli TP, et al. Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis. Cancer Med. 2016;5(6):1098–1107.
   PubMed Web of Science ®Google Scholar
• Bonet M, Bonfill T, Nunez M, et al. Curative radiation therapy for very elderly bladder cancer patients with localized disease. Clin Transl Oncol. 2018;20(7):899–905.
   PubMed Web of Science ®Google Scholar
• Hammer L, Laufer M, Dotan Z, et al. Accelerated hypofractionated radiation therapy for elderly frail bladder cancer patients unfit for surgery or chemotherapy. Am J Clin Oncol. 2019;42(2):179–183.
   PubMed Web of Science ®Google Scholar
• Lutkenhaus LJ, van Os RM, Bel A, et al. Clinical results of conformal versus intensity-modulated radiotherapy using a focal simultaneous boost for muscle-invasive bladder cancer in elderly or medically unfit patients. Radiat Oncol. 2016;11:45.
   PubMed Web of Science ®Google Scholar
• McPherson VA, Rodrigues G, Bauman G, et al. Chemoradiotherapy in octogenarians as primary treatment for muscle-invasive bladder cancer. Can Urol Assoc J. 2017;11(1–2):24–30.
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Maebayashi T, Aizawa T, et al. Clinical results for bladder cancer treated by radiotherapy without concurrent standard chemotherapy. Anticancer Res. 2016;36(10):5519–5525.
   PubMed Web of Science ®Google Scholar
• Santacaterina A, Platania A, Palazzolo C, et al. Very elderly (>80 years), frail patients with muscle-invasive bladder cancer and comorbidities: is curative irradiation feasible? Tumori. 2015;101(6):609–613.
   PubMed Web of Science ®Google Scholar
• Tran E, Souhami L, Tanguay S, et al. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer. Am J Clin Oncol. 2009;32(4):333–337.
   PubMed Web of Science ®Google Scholar
• Turgeon GA, Souhami L, Cury FL, et al. Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2014;88(2):326–331.
   PubMed Web of Science ®Google Scholar
• Wujanto C, Tey J, Chia D, et al. Radical radiotherapy in older patients with muscle invasive bladder cancer. J Geriatr Oncol. 2019;10(2):292–297.
   PubMed Web of Science ®Google Scholar
• Hollenbeck BK, Miller DC, Taub D, et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology. 2004;64(2):292–297.
   PubMed Web of Science ®Google Scholar
• Gray PJ, Fedewa SA, Shipley WU, et al. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the national cancer data base. Eur Urol. 2013;63(5):823–829.
   PubMed Web of Science ®Google Scholar
• VanderWalde NA, Chi MT, Hurria A, et al. Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit. World J Urol. 2016;34(1):3–11.
   PubMed Web of Science ®Google Scholar
• Martini A, Sfakianos JP, Renström-Koskela L, et al. The natural history of untreated muscle-invasive bladder cancer. BJU Int. 2020;125(2):270–275.
   PubMed Web of Science ®Google Scholar
• Kimura S, Mari A, Foerster B, et al. Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: a systematic review and Meta-Analysis. J Urol. 2019;201(1):46–53.
   PubMed Web of Science ®Google Scholar
• Chung PW, Bristow RG, Milosevic MF, et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol. 2007;25(4):303–309.
   PubMed Web of Science ®Google Scholar
• Ripping TM, Kiemeney LA, van Hoogstraten LMC, et al. Insight into bladder cancer care: study protocol of a large nationwide prospective cohort study (BlaZIB). BMC Cancer. 2020;20(1):455.
   PubMed Web of Science ®Google Scholar